Summary

Cygnal Therapeutics

Founded in 2017

Description

Cygnal Therapeutics is a biotechnology company founded in 2017 by Flagship Pioneering. They are focused on developing drugs in the field of exoneural biology, starting with cancer and inflammatory diseases. Their Exoneural Medicine Platform allows the...

Strengths

  • Cygnal Therapeutics has a strong market share in their industry
  • Revenue generated per employee is greater than industry average
  • Demonstrating revenue growth that is faster than the industry average
  • The number of employees is growing faster than the industry average
  • Revenue growth is more steady than the industry average
  • Since Cygnal Therapeutics was founded, the company has grown faster than the industry average

Annual Revenue

Cygnal Therapeutics's annual revenue

$10195000

Based on Kona Equity data

  • Revenue per employee

    $509750

  • Variance of revenue growth

    0.01

  • Annual revenue growth since founding

    $1456428

  • Revenue growth rate from first known quarter to current

    29.2%

Employee Count

20 employees

  • Employee growth rate from first known quarter to current

    29.4%

Executives

Daniel Blom

Vice President, Biologics Drug Discovery

d**@cygnaltx.com

Douglas Campbell

Vice President, Finance

d**@cygnaltx.com

Jared Subiono

Research Assistant

j**@cygnaltx.com

Kidist Aklilu

Senior Researcher Associate At Therapeutics

k**@cygnaltx.com

Nicole Carta

Vice President, Human Resources

n**@cygnaltx.com

Ryan Zhang

Research Co Op Associate

r**@cygnaltx.com

Deanna Sumrein

Recruiting Coordinator

d**@cygnaltx.com

Ljiljana Minwalla

Senior Vice President

l**@cygnaltx.com

Eugene Chekler

Director, Medicinal Chemistry

e**@cygnaltx.com

James Searson

Research Associate

j**@cygnaltx.com

Pauline Mcgowan

Senior VP, Finance

p**@cygnaltx.com

Guang Liu

Director, Hit Generation Science

g**@cygnaltx.com

Ishita Majumdar

Scientist

i**@cygnaltx.com

Kai-Chih Huang

Imaging Data Scientist

k**@cygnaltx.com

Timothy Zheng

Senior Vice President, Biology

t**@cygnaltx.com

Jijun Dong

Executive Director

j**@cygnaltx.com

Andrea Park

Intern

a**@cygnaltx.com

Sarah Nesti

Senior Research Associate

s**@cygnaltx.com

Alexandria Fink

Research Associate

a**@cygnaltx.com

Anthony Bombard

Manager, Office of the President and Chief Executive Officer

a**@cygnaltx.com

Mandana Abbassi

Research Principal & Vivo Associate

m**@cygnaltx.com

Kiley Cuoto

Scientist

k**@cygnaltx.com

Daniela Maiz

Research Associate

d**@cygnaltx.com

G Score - 6

The G Score is an eight-point scale where firms are given a score of 1 for each of the criteria that they pass. The G score compares a company against the industry median to find those that are healthy and growing.

  • G1 Revenue is greater than the industry median.
  • G2 Income per employee more than industry average.
  • G3 Revenue growth rate from the first known quarter to current is higher than the industry average.
  • G4 Employee growth rate from the first known quarter to current is higher than the industry average.
  • G5 Variance of revenue growth is less than the industry average
  • G6 Annual revenue growth since founding is higher than the industry average.

Location

325 Vassar St, Ste 2B 
Cambridge, MA  02139

Unlock unlimited leads

Get access to millions of contacts, companies, emails, and more!

Similar Companies

kddsystems.com

kddsystems.com
  • Location: New York, NY
  • Annual Revenue: $1.8M
  • Employees: 20

TetraGenetics

tetragenetics.com
  • Founded in 2004
  • Location: Arlington, MA
  • Annual Revenue: $2.4M
  • Employees: 13
  • Using ciliate Tetrahymena to produce high-quality biologics, vaccines, and diagnostic tools to improve Global Health. Gates Grand Challenge Grant winner.

Progenra Inc

progenra.com
  • Founded in 2002
  • Location: Malvern, PA
  • Annual Revenue: $3.9M
  • Employees: 14
  • Progenra is Dedicated to Finding New Medicines Through Targeting the Ubiquitin Proteasome System to fill unmet needs in a spectrum of therapeutic areas.

GENOSCO INC

genosco.com
  • Founded in 2008
  • Location: Cambridge, MA
  • Annual Revenue: $4.0M
  • Employees: 18
  • A clinical-stage biotechnology company pursuing the discovery and development of novel small-molecule drugs to treat patients with unmet medical needs.

ActivX Biosciences Inc

activx.com
  • Founded in 2000
  • Location: La Jolla, CA
  • Annual Revenue: $7.9M
  • Employees: 33
  • ActivX Biosciences is an emerging biopharmaceutical company that specializes in the discovery and development of highly selective, best-in-class, small molecule drugs for major unmet medical needs. With a focus on hematology, oncology, metabolic, and i...

Excepgen

excepgen.com
  • Founded in 2018
  • Location: San Francisco, CA
  • Annual Revenue: $631.0K
  • Employees: 3
  • ExcepGen is a venture-backed, early-stage biotechnology company located in San Francisco. The company is focused on engineering therapeutics that adapt with cellular regulation to eliminate disease. They specialize in gene therapies and vaccines powere...

Key Information

  • SIC: 80; 283
  • NAICS: 541; 5417
Disclaimer: These numbers are estimates and any other company information is based off our proprietary algorithms and by no means should be accepted as 100% factual. Kona Equity is in no way affiliated with Cygnal Therapeutics.

See similar companies

Frequently Asked Questions

Where is Cygnal Therapeutics located?

Cygnal Therapeutics's headquarters are located at 325 Vassar St, Ste 2B  Cambridge, MA  02139.


What is Cygnal Therapeutics's official website?

Cygnal Therapeutics's official website is cygnaltx.com


What is Cygnal Therapeutics's revenue?

Cygnal Therapeutics's annual revenue is $10.2 M.


What is Cygnal Therapeutics's SIC code?

Cygnal Therapeutics's SIC: 80; 283


What is Cygnal Therapeutics's NAICS code?

Cygnal Therapeutics's NAICS: 541; 5417.


How many employees does Cygnal Therapeutics's have?

Cygnal Therapeutics has 20 employees


What industry does Cygnal Therapeutics belong to?

Cygnal Therapeutics is in the industry of Biotechnology.

Next step

Visitors review